Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 5/20 | 0.36 |
| ▸ | UBA3 | Q8TBC4 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23456080 | 1.00 | NAE1 (0.36) | NAE1UBA3CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL24165806 | 1.00 | NAE1 (0.36) | NAE1UBA3CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL23456007 | 0.94 | NAE1 (0.34) | NAE1UBA3CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL23456140 | 0.84 | — | — | |
| SCHEMBL23456120 | 0.83 | NAE1 (0.30) | NAE1UBA3 | |
| SCHEMBL23487494 | 0.83 | NAE1 (0.30) | NAE1UBA3 | |
| SCHEMBL23487858 | 0.83 | NAE1 (0.30) | NAE1UBA3 | |
| SCHEMBL23455960 | 0.82 | NAE1 (0.49) | NAE1UBA3CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL23487495 | 0.82 | NAE1 (0.49) | NAE1UBA3CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL22401426 | 0.82 | NAE1 (0.49) | NAE1UBA3CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-08-06 | — | — | US | disclosed |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542293-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | NAE1 1571/4885UBA3 2354/4885CYP3A4 4560/4885 |
| US-20240209017-A1 | STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING | STING1, CGAS, MAVS | NAE1 1571/4885UBA3 2354/4885CYP3A4 4560/4885 |
| US-12054512-B2 | Sting modulator compounds, and methods of making and using | STING1, CGAS, MAVS | NAE1 1571/4885UBA3 2354/4885CYP3A4 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.